VICTOZA (liraglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2010.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
VICTOZA (liraglutide) is a GLP-1 receptor agonist approved in 2010 for type 2 diabetes management. It mimics glucagon-like peptide-1, stimulating insulin secretion and reducing glucagon when blood glucose is elevated. The drug is administered as a subcutaneous injection and represents a foundational therapy in the GLP-1 class.
VICTOZA operates in a mature, highly competitive GLP-1 market with 15 competing entities; commercial teams face consolidation and portfolio rationalization pressures.
Glucagon-like Peptide-1 (GLP-1) Agonists
GLP-1 Receptor Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Efficacy of Liraglutide Therapy in Patients With IPAA
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Worked on VICTOZA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VICTOZA offers exposure to managed diabetes care, payer dynamics, and portfolio rationalization in a mature GLP-1 market. Career growth requires expertise in market access, price defense, and managed decline rather than launch or expansion.